Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHENASDAQ:ATRANASDAQ:KPRXNASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$3.99+5.3%$3.54$1.00▼$5.87$35.38M0.65143,067 shs27,919 shsATRAAtara Biotherapeutics$6.84-10.1%$6.66$5.01▼$18.71$40.77M0.3124,364 shs114,071 shsKPRXKiora Pharmaceuticals$3.23+3.2%$3.04$2.51▼$5.55$9.83M-0.6731,052 shs13,094 shsRNXTRenovoRx$1.18+6.3%$0.97$0.75▼$1.69$43.13M1.1281,574 shs411,694 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-7.56%-10.40%+14.85%-14.25%+85.78%ATRAAtara Biotherapeutics+15.13%+2.56%+27.26%-11.41%-52.44%KPRXKiora Pharmaceuticals+1.29%+0.32%+12.19%-13.54%-32.47%RNXTRenovoRx+5.71%+5.11%+23.33%+6.73%-19.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics2.5633 of 5 stars3.35.00.00.02.51.70.0ATRAAtara Biotherapeutics4.2135 of 5 stars3.33.00.04.72.12.50.6KPRXKiora Pharmaceuticals3.4627 of 5 stars3.85.00.00.03.11.70.6RNXTRenovoRx2.2003 of 5 stars3.53.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00200.75% UpsideATRAAtara Biotherapeutics 2.57Moderate Buy$17.75159.50% UpsideKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00209.60% UpsideRNXTRenovoRx 3.00Buy$7.00493.22% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, ATHE, RNXT, and ATRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.003/11/2025ATRAAtara BiotherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AATRAAtara Biotherapeutics$128.94M0.32N/AN/A($24.34) per share-0.28KPRXKiora Pharmaceuticals$16M0.61N/AN/A$7.14 per share0.45RNXTRenovoRx$43K1,003.05N/AN/A($0.28) per share-4.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$12.97N/AN/AN/A-132.58%N/A-90.16%N/AKPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%N/ARNXTRenovoRx-$10.23M-$0.39N/AN/AN/AN/A-205.96%-110.01%N/ALatest KPRX, ATHE, RNXT, and ATRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/15/2025Q1 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 million3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million3/7/2025Q4 2024ATRAAtara Biotherapeutics-$3.82-$1.19+$2.63-$1.19$20.58 million$32.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.543.54ATRAAtara BiotherapeuticsN/A0.590.50KPRXKiora PharmaceuticalsN/A8.978.97RNXTRenovoRxN/A5.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%ATRAAtara Biotherapeutics70.90%KPRXKiora Pharmaceuticals76.97%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%ATRAAtara Biotherapeutics3.70%KPRXKiora Pharmaceuticals0.05%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.35 millionNot OptionableATRAAtara Biotherapeutics3305.96 million5.55 millionOptionableKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionableRNXTRenovoRx636.55 million22.30 millionNot OptionableKPRX, ATHE, RNXT, and ATRA HeadlinesRecent News About These CompaniesRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16 at 9:27 PM | finance.yahoo.comLe BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisionsMay 15 at 9:39 PM | fr.investing.comTranscription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentesMay 15 at 9:39 PM | fr.investing.comRenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptMay 15 at 9:15 PM | seekingalpha.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue EstimatesMay 15 at 8:31 PM | zacks.comRenovoRx Reports First Quarter 2025 Financial Results and Business HighlightsMay 15 at 4:19 PM | businesswire.comEarnings Preview For RenovoRxMay 14 at 2:02 PM | benzinga.comRenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21stMay 14 at 9:01 AM | finance.yahoo.comU.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy PlatformMay 6, 2025 | finance.yahoo.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRxApril 30, 2025 | zonebourse.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-PacApril 29, 2025 | zonebourse.comJohns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréasApril 29, 2025 | fr.investing.comJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29, 2025 | finance.yahoo.comRenovoRx ramps up production of FDA-cleared RenovoCathApril 18, 2025 | uk.investing.comRamtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) StockApril 18, 2025 | insidertrades.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions pour 13.500$April 18, 2025 | fr.investing.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions ordinaires pour 13.500€April 18, 2025 | fr.investing.comRenovorx augmente sa production américaine de dispositifs Renovocath pour répondre à la demande croissante de la communauté oncologiqueApril 16, 2025 | zonebourse.comLe PDG de RenovoRx, Shaun Bagai, acquiert des actions ordinaires pour 6.821$April 16, 2025 | fr.investing.comRenovoRx augmente la production de son dispositif RenovoCath approuvé par la FDAApril 16, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockAmerican Express: Affluent Customers Don’t Leave Home Without It By Jea Yu | April 26, 2025View American Express: Affluent Customers Don’t Leave Home Without It KPRX, ATHE, RNXT, and ATRA Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$3.99 +0.20 (+5.28%) Closing price 03:58 PM EasternExtended Trading$3.98 -0.01 (-0.13%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Atara Biotherapeutics NASDAQ:ATRA$6.84 -0.77 (-10.12%) Closing price 04:00 PM EasternExtended Trading$6.93 +0.09 (+1.32%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Kiora Pharmaceuticals NASDAQ:KPRX$3.23 +0.10 (+3.19%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.02 (+0.46%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.RenovoRx NASDAQ:RNXT$1.18 +0.07 (+6.31%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.42%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
